|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
|
30808625 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study.
|
28772007 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This group also had higher peripheral disease activity (imaging only vs clinical AxPsA: mean (SD) tender joint count 5.3 (6.1) vs 3.3 (4.7), swollen joint count 1.9 (2.9) vs 1.2 (2.4); p < 0.001 for both comparisons) and was less often treated using TNF inhibitors (16.1 vs 38.2%; p < 0.001) than patients who were classified as axPsA.
|
29948352 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual neutralization of TNF and IL-17A with ABT-122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12-week treatment course in patients with PsA.
|
29855175 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF blockers are highly efficacious at dampening inflammation and reducing symptoms in rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and also in nonrheumatic syndromes such as inflammatory bowel disease.
|
28275260 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite the introduction of new molecules with different mechanisms of action, the role of anti-TNF in the treatment of all disease manifestations of this intriguing disease is still central.<b>Areas covered</b>: The aim of this paper is to review the role of anti-TNF drugs in the treatment of different disease domains in PsA (peripheral and axial joints, skin, enthesis, patient's reported outcomes, extra-articular manifestations), reporting data from randomized clinical trials and observational studies.
|
31652079 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
This retrospective study aimed to evaluate the long-term efficacy and effects on lipid profile and Atherogenic Index of antitumor necrosis factor (TNF)α therapy with adalimumab in patients with moderate-to-severe psoriasis or psoriatic arthritis.
|
29564871 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Twenty (20) of the PA patients were also tested for the ability of their stimulated cells to secrete Interleukin-1 (IL-1 beta) and tumor necrosis factor (TNF alpha).
|
9548075 |
1998 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fecal samples from PsA/SpA patients pre- and post-treatment with tumor necrosis factor inhibitors (TNFi; n=15) or an anti-interleukin (IL)-17A monoclonal antibody inhibitor (IL-17i; n=14) underwent sequencing (16S, ITS and shotgun metagenomics) and computational microbiome analysis.
|
31729183 |
2020 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To evaluate the risk of AF and major adverse cardiovascular events (MACE) associated with use of ustekinumab vs tumor necrosis factor inhibitors (TNFi) in patients with psoriasis or psoriatic arthritis.
|
30916734 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
These drugs block TNFα from interacting with its receptors and have enabled the development of breakthrough therapies for the treatment of several autoimmune inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis.
|
29518978 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
|
31321485 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Such genes are involved in molecular pathways crucial for PsA pathogenesis, including immune response, glycolipid metabolism, bone remodeling, type 1 interferon, wingless related integration site, and tumor necrosis factor signaling.
|
30061880 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of single-nucleotide polymorphisms (SNPs) at positions -238, -308, and +489 of the TNF-α gene in the genetic susceptibility to PsA, in the severity of the disease, and, finally, in the response to TNF-α inhibitors (adalimumab, etanercept, or infliximab).
|
24594669 |
2014 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical trials have reported the effectiveness of numerous biologics with different targets, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-17 receptor, IL-12/23(p40), and IL-23(p19) for the treatment of PsA.
|
30891646 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study assessed the use of scintigraphy and magnetic resonance imaging (MRI) in identifying the presence and amount of tumour necrosis factor-α (TNF-α) in the joint or skin of patients with psoriatic arthritis, to guide the course of treatment more efficiently.
|
27937056 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis.
|
30247726 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
|
22480748 |
2012 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A pilot study of the association of tumor necrosis factor alpha polymorphisms with psoriatic arthritis in the Romanian population.
|
21954344 |
2011 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association to PsA was observed in the presence of polymorphisms: TNF-238 G > A (rs361525), -308 G > A (rs1800629), and -857 C > T (rs1799724); IL12B C > G (rs6887695) and A > C (rs3212227); IL23A A > G (rs2066808) and IL23R G > A (rs11209026).
|
30584776 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined the expression of ILT4 and analysed the relationship with the expression of costimulatory proteins and tumor necrosis factor-α (TNF-α) production in monocytes from patients with psoriatic arthritis (PsA) starting anti-TNF treatment.
|
24676037 |
2014 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
If TNF inhibitors are initiated in the early stages of psoriatic arthritis, this could potentially modulate disease and therefore allow us to discontinue the TNF inhibitor after achieving remission.
|
31521192 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with PsA enrolled in the Corrona Registry between 2005 and 2013 were followed from initiation of a TNF inhibitor (TNFi; etanercept, adalimumab, infliximab, certolizumab, or golimumab) to the visit closest to 12 months.
|
30647182 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that allelic variations at the TNFalpha locus influence susceptibility to PsA.
|
11830425 |
2002 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Improved knowledge of the immune/inflammatory pathways, which characterise the pathophysiology of rheumatoid arthritis (RA) and seronegative spondyloarthropathies (SpA), such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have provided the link between inflammation and bone loss, via a complex network of bone cells, T and B cells, pro-inflammatory cytokines such as TNF-α, IL1, IL6, IL17, IL23, costimulator molecules, signalling pathways including both RANKL/RANK/OPG and Wnt signallings.
|
30557124 |
2019 |